Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Initial Safety and Preliminary Efficacy of the Novelrad Vascular Closure System (NVCS)

29 de setembro de 2026 atualizado por: Novelrad Ltd.

A First in Human (FIH) Clinical Study to Evaluate the Initial Safety and Preliminary Efficacy of the Suture-Mediated Novelrad Vascular Closure System

This study evaluates the initial safety and preliminary efficacy of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths.

Visão geral do estudo

Descrição detalhada

The Novelrad Vascular Closure System (NVCS) is an investigational suture-mediated vascular closure device intended for use following percutaneous interventional catheterization procedures performed through the common femoral artery using large-bore procedural sheaths. The NVCS is designed to facilitate percutaneous closure of the arteriotomy using a continuous suture technique.

The study is being conducted to evaluate the initial safety and preliminary efficacy of the NVCS in subjects undergoing percutaneous interventional catheterization procedures using large-bore procedural sheaths.

Tipo de estudo

Intervencional

Inscrição (Real)

15

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Jerusalem, Israel
        • Hadassah Medical Center
      • Jerusalem, Israel
        • Shaare Zedek Medical Center
      • Tel Aviv, Israel
        • Sourasky Tel-Aviv Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subject is ≥18 years old.
  2. Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
  3. Subject has suitable sized vessel / calcification as evaluated on pre-procedural CT angiography by the investigator and by the study' screening committee
  4. Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
  5. Understand and sign the study specific written informed consent form
  6. Able and willing to fulfill the follow-up requirements

Exclusion Criteria:

Baseline Exclusions:

  1. Known to be pregnant or lactating.
  2. Immunocompromised or with pre-existing autoimmune disease.
  3. Systemic infection or a local infection at or near the access site.
  4. Significant anemia (Hgb < 9 g/dL hematocrit <30%).
  5. Morbidly obese or cachectic (BMI >40 kg/m2 or <20kg/m2).
  6. Known bleeding disorders including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability.
  7. Known allergy to any device component.
  8. Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
  9. Common femoral artery with calcium, as determined by baseline CTA, precluding safe access in the opinion of the investigator or severe peripheral vascular disease as evidenced by severe claudication when ambulating < 30 meter, weak or absent pulses in the affected limb.
  10. Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
  11. Prior target artery closure with any closure device < 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
  12. Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
  13. Undergoing therapeutic thrombolysis.
  14. Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR >1.8 at the time of the procedure.
  15. Subject unable to be adequately anti-coagulated for the procedure.
  16. Subjects who are not mobile and are confined to a wheelchair or bed.
  17. ST-elevation MI within 45 days prior to procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
  18. NYHA class IV heart failure.
  19. Left ventricular ejection fraction <20%.
  20. Unilateral or bilateral lower extremity amputation.
  21. Renal insufficiency (serum creatinine >2.5 mg/dl) or on dialysis therapy, or after renal transplant.
  22. Existing nerve damage in the NVCS treated leg.
  23. Further planned endovascular procedure within the next 30 days.
  24. Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
  25. Subject cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
  26. Common femoral artery <6mm or >50% diameter femoral stenosis by baseline CTA and/or severe peripheral arterial disease or Rutherford Classification 5 or 6.
  27. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  28. Known severe allergy to contrast reagent that cannot be managed with premedication.
  29. Connective tissue disease (e.g., Marfan's Syndrome).
  30. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure.
  31. Subject is mentally incompetent or a prisoner.
  32. Planned antegrade puncture during the index procedure.
  33. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
  34. Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed).

Intra-Procedure Exclusions:

  1. On baseline Duplex US the Common femoral artery <6mm or >50% stenosis of the femoral artery.
  2. Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
  3. Common femoral artery suspected to have experienced a back wall puncture or underwent > one (1) arterial puncture during the catheterization procedure.
  4. Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device.
  5. Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
  6. Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
  7. Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
  8. Planned antegrade puncture during the index procedure.
  9. Possible bacterial contamination of the procedure's sheath or surrounding tissues during the procedure.
  10. Intra-procedural complication(s) at the femoral access site before procedural sheath removal and before sliding the NVCS knot down, including: 1. Bleeding or swelling around the sheath that may indicate hematoma formation and/or pseudoaneurysm formation; and 2. Peri-procedural duplex us/angiographic evidence of thrombus formation or significant injury in the aorta or iliac vessels associated with procedural large bore sheath placement and/or sub-optimal anticoagulation.
  11. Presence of ipsilateral femoral venous sheath during the interventional procedure.
  12. Systolic blood pressure <90 mm Hg just prior to planned vascular closure without the ability to increase it.
  13. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  14. Index procedure planned sheath or interventional device >22Fr during the procedure.
  15. Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCS.
  16. Duplex US (or by angiography if applicable) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.
  17. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Novelrad Vascular Closure System (NVCS)

The Novelrad Vascular Closure System (NVCS), will be used in subjects who are undergoing diagnostic or interventional catheterization procedures

NVCS will be used to close the common femoral artery access site while reducing time-to-hemostasis in subjects who have undergone diagnostic or interventional catheterization procedures using 8-22 French (F) Sheaths.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety: Freedom from major complications of the target limb within 30 days following the procedure
Prazo: Within 30 days post-procedure

Assessment of the incidence of protocol defined major complications of the target limb access site through 30 days post procedure as specified in the protocol.

Within 30 days post-procedure
Efficacy: Mean Time to Hemostasis
Prazo: Periprocedural

The Time to Hemostasis is defined as the elapsed time between withdrawal of index procedure sheath from common femoral artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).

Periprocedural

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Safety: Frequency of minor complications at the target limb.
Prazo: Within 30 days post procedure

Assessment of the incidence of minor complications of the target limb access site as specified in the protocol.

Within 30 days post procedure
Efficacy: Technical Success
Prazo: Periprocedural

Achievement of hemostasis with the NVCS without the need for any access-site-related adjunctive surgical or endovascular intervention (target limb only).

Periprocedural
Efficacy: Treatment/Procedure Success
Prazo: Within 30 days post procedure

Subjects with technical success and free from major complications through 30 days follow-up.

Within 30 days post procedure
Efficacy: Mean Time for NVCS Procedure
Prazo: Periprocedural

The elapsed time from initial skin break (first needle insertion) to time when the suture is released from the NVCD plus the elapsed time from performing the knot at the end of the index procedure and until hemostasis is achieved.

Periprocedural
Efficacy: Mean Time to Ambulation
Prazo: Within 24 hours after procedural sheath removal

The elapsed time between last procedural sheath removal and when ambulation is achieved (subject is standing and walking at least 6-meters without bleeding).

Within 24 hours after procedural sheath removal
Time-to-discharge eligibility
Prazo: Within 48 hours after the procedure

The time following the removal of the NVCS and when the patient is eligible for discharge based solely on (1) completion TTA, (2) freedom from orthostatic hypotension [defined as stable blood pressure and heart rate after ambulating], (3) ability to void and, (4) a stable access site without bleeding or expansion of a prior hematoma.

Within 48 hours after the procedure
Efficacy: Percent of subjects with surgical or endovascular intervention post closure
Prazo: Periprocedural

Subjects require adjunctive surgical or endovascular intervention to achieve hemostasis of the NVCS access site.

Periprocedural
Efficacy: Percent of subjects with NVCS Failure
Prazo: Periprocedural

When the device is used in accordance with the IFU, but does not perform as described in the IFU, and/or negatively impacts treatment of the study subject.

Periprocedural

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Yossi Muncher, Ph.D., Novelrad Ltd.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de novembro de 2025

Conclusão Primária (Real)

18 de agosto de 2026

Conclusão do estudo (Real)

18 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de setembro de 2026

Primeira postagem (Real)

5 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NVCS-CLN-001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever